Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Freeman

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Mbio|April 5, 2023
Penicillin Binding Protein Substitutions Cooccur with Fluoroquinolone Resistance in Epidemic Lineages of Multidrug-Resistant Clostridioides difficileKate E Dingle, Jane Freeman, Xavier Didelot, et al.
Antibiotics (Basel, Switzerland)|March 29, 2023
Non-Toxigenic <i>Clostridioides difficile</i> Strain E4 (NTCD-E4) Prevents Establishment of Primary <i>C. difficile</i> Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut ModelPerezimor Etifa, César Rodríguez, Céline Harmanus, et al.
BMJ Open|January 31, 2025
plaTform fOr Urinary tract infection diagnostiC evAluatioN (TOUCAN): a protocol for a prospective diagnostic accuracy study of point-of-care testing in patients suspected of acute uncomplicated urinary tract infection in primary care clinics in EnglandPhilip J Turner, Thomas R Fanshawe, Jane Freeman, et al.
The Lancet. Infectious Diseases|January 25, 2026
Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled studyThomas Louie, Wendy Ribble, Louis Boccumini, et al.
The Journal of Biological Chemistry|December 3, 2023
Clostridioides difficile canonical L,D-transpeptidases catalyze a novel type of peptidoglycan cross-links and are not required for beta-lactam resistanceNicola F Galley, Darren Greetham, Marcel G Alamán-Zárate, et al.
Nature Communications|July 12, 2023
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficileAbiola O Olaitan, Chetna Dureja, Madison A Youngblom, et al.
The Journal of Infection|July 3, 2020
Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in EnglandColin S Brown, Kathryn Clare, Meera Chand, et al.
Blood Advances|September 18, 2023
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphomaLoretta J Nastoupil, Georg Hess, Miguel A Pavlovsky, et al.
The Lancet. Infectious Diseases|January 29, 2017
Effects of control interventions on Clostridium difficile infection in England: an observational studyKate E Dingle, Xavier Didelot, T Phuong Quan, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Mbio|April 5, 2023
Penicillin Binding Protein Substitutions Cooccur with Fluoroquinolone Resistance in Epidemic Lineages of Multidrug-Resistant Clostridioides difficileKate E Dingle, Jane Freeman, Xavier Didelot, et al.
Antibiotics (Basel, Switzerland)|March 29, 2023
Non-Toxigenic <i>Clostridioides difficile</i> Strain E4 (NTCD-E4) Prevents Establishment of Primary <i>C. difficile</i> Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut ModelPerezimor Etifa, César Rodríguez, Céline Harmanus, et al.
BMJ Open|January 31, 2025
plaTform fOr Urinary tract infection diagnostiC evAluatioN (TOUCAN): a protocol for a prospective diagnostic accuracy study of point-of-care testing in patients suspected of acute uncomplicated urinary tract infection in primary care clinics in EnglandPhilip J Turner, Thomas R Fanshawe, Jane Freeman, et al.
The Lancet. Infectious Diseases|January 25, 2026
Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled studyThomas Louie, Wendy Ribble, Louis Boccumini, et al.
The Journal of Biological Chemistry|December 3, 2023
Clostridioides difficile canonical L,D-transpeptidases catalyze a novel type of peptidoglycan cross-links and are not required for beta-lactam resistanceNicola F Galley, Darren Greetham, Marcel G Alamán-Zárate, et al.
Nature Communications|July 12, 2023
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficileAbiola O Olaitan, Chetna Dureja, Madison A Youngblom, et al.
The Journal of Infection|July 3, 2020
Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in EnglandColin S Brown, Kathryn Clare, Meera Chand, et al.
Blood Advances|September 18, 2023
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphomaLoretta J Nastoupil, Georg Hess, Miguel A Pavlovsky, et al.
The Lancet. Infectious Diseases|January 29, 2017
Effects of control interventions on Clostridium difficile infection in England: an observational studyKate E Dingle, Xavier Didelot, T Phuong Quan, et al.
Pageof 6